SUMMIT, N.J.–(BUSINESS WIRE) May 28, 2019 — Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) approved Revlimid (lenalidomide) in combination with a rituximab product (R²) for the treatment of…Original Article
You may also like
FDA Approves Hympavzi (marstacimab-hncq) for the...
FDA Approves Itovebi (inavolisib) for the Combination...
U.S. Food and Drug Administration Approves...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar...
Dupixent Approved in the US as the First-Ever Biologic...
FDA Approves Flyrcado (flurpiridaz F 18) Radioactive...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.